Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Anavex Life Sciences Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AVXL
Nasdaq
8731
https://www.anavex.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Anavex Life Sciences Corp
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
- Apr 11th, 2024 11:30 am
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Mar 25th, 2024 11:30 am
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
- Mar 18th, 2024 11:30 am
12 $10 Stocks That Will Triple
- Feb 26th, 2024 6:14 pm
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
- Feb 26th, 2024 12:30 pm
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript
- Feb 8th, 2024 2:39 pm
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
- Feb 7th, 2024 12:30 pm
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
- Feb 1st, 2024 12:30 pm
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
- Jan 31st, 2024 5:18 pm
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
- Jan 31st, 2024 5:11 pm
Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 530.68%: Here's is How to Trade
- Jan 31st, 2024 2:55 pm
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
- Jan 24th, 2024 5:00 pm
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
- Jan 24th, 2024 12:30 pm
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
- Jan 16th, 2024 12:30 pm
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
- Jan 9th, 2024 1:44 pm
5 Small-Cap Stocks to Play the January Effect
- Jan 8th, 2024 2:59 pm
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
- Jan 8th, 2024 12:30 pm
Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results
- Jan 3rd, 2024 2:51 pm
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:30 pm
Anavex Life Sciences Provides an Update on Rett Syndrome Program
- Jan 2nd, 2024 1:00 pm
Scroll